Teva Pharmaceuticals Plans Senior Notes Offering to Refinance Existing Debt

Teva Pharmaceutical Industries Ltd. announced plans to issue new senior notes in euros and U.S. dollars via its finance subsidiaries. The offering's primary goal is to refinance existing debt, including sustainability-linked and high-coupon notes maturing from 2027 to 2029. This move seeks to optimize Teva's debt structure, potentially enhancing financial flexibility and reducing interest costs, contingent on market conditions.